XML 71 R60.htm IDEA: XBRL DOCUMENT
v3.23.3

Key Management Personnel Disclosures (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2023
Statement [LineItems] |
Summary of Directors and Key Management Personnel Compensation | (a) Directors and key management personnel compensation
|  | Consolidated |
|  | June 30, 2023 A$ |  |  | June 30, 2022 A$ |  |  | June 30, 2021 A$ |
Short-term employee benefits |  |  | 1,471,671 |  |  |  | 1,341,126 |  |  |  | 1,399,536 |
Long-term employee benefits |  |  | 11,967 |  |  |  | 13,091 |  |  |  | 9,059 |
Post-employment benefits |  |  | 54,548 |  |  |  | 47,611 |  |  |  | 157,001 |
Share-based payments |  |  | 1,380,074 |  |  |  | 1,110,757 |  |  |  | 1,278,490 |
|  |  | 2,918,260 |  |  |  | 2,512,585 |  |  |  | 2,844,086 |
Ordinary Shares [member] |
Statement [LineItems] |
Summaries of All STI and LTI Performance Rights Granted Under the EIP | The numbers of shares in the company held during the year by each director of and other key management personnel of the Group, including their personally related parties, are set out below. There were no shares granted during the reporting period as compensation. On November 5, 2019, there was a 10 to 1 share consolidation. The number of shares in the fiscal years 2023, 2022 and 2021 tables below are prepared on post share consolidation basis.
|  |  |  |  | Received during the |  |  |  |  |  |  |  |  |  |
|  | Balance at start |  |  | fiscal year |  |  | Received during the |  |  | Other changes |  |  | Balance at end |
|  | of the |  |  | on exercise of |  |  | fiscal year on the |  |  | during the |  |  | of the |
June 30, 2023 |  | fiscal year |  |  | performance rights |  |  | exercise of options |  |  | fiscal year # |  |  | fiscal year |
Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr Russell Howard |  |  | 1,000,000 |  |  |  | 113,207 |  |  |  | — |  |  |  | — |  |  |  | 1,113,207 |
Mr Pete Meyers |  |  | 2,274,395 |  |  |  | 500,000 |  |  |  | — |  |  |  | — |  |  |  | 2,774,395 |
Mr Marc Voigt |  |  | 8,847,445 |  |  |  | 2,400,000 |  |  |  | — |  |  |  | — |  |  |  | 11,247,445 |
Dr Frédéric Triebel |  |  | 7,753,764 |  |  |  | 900,000 |  |  |  | — |  |  |  | — |  |  |  | 8,653,764 |
Ms Lucy Turnbull |  |  | 3,284,126 |  |  |  | 92,966 |  |  |  | — |  |  |  | (3,377,092 | )* |  |  | — |
Ms Lis Boyce |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  | — |
Ms Deanne Miller |  |  | 2,767,305 |  |  |  | 600,000 |  |  |  | — |  |  |  | (100,000 | ) |  |  | 3,267,305 |
Total ordinary shares |  |  | 25,927,035 |  |  |  | 4,606,173 |  |  |  | — |  |  |  | (3,477,092 | ) |  |  | 27,056,116 |
ADSs |  |  |  |  |  |  |  |  |  |  | — |  |  |  |  |  |  |  |  |
Mr Marc Voigt |  |  | 45 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 45 |
Dr Frédéric Triebel |  |  | 17,061 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 17,061 |
Total ADSs |  |  | 17,106 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 17,106 |
# | Other changes during the year includes on market acquisitions and/or disposals
* | This change during the year represents derecognition due to the cessation of the director’s position
|  |  |  |  | Received during the |  |  |  |  |  |  |  |  |  |
|  | Balance at start |  |  | fiscal year |  |  | Received during the |  |  | Other changes |  |  | Balance at end |
|  | of the |  |  | on exercise of |  |  | fiscal year on the |  |  | during the |  |  | of the |
June 30, 2022 |  | fiscal year |  |  | performance rights |  |  | exercise of options |  |  | fiscal year # |  |  | fiscal year |
Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr Russell Howard |  |  | 750,000 |  |  |  | 250,000 |  |  |  | — |  |  |  | — |  |  |  | 1,000,000 |
Mr Pete Meyers |  |  | 1,774,395 |  |  |  | 500,000 |  |  |  | — |  |  |  | — |  |  |  | 2,274,395 |
Mr Marc Voigt |  |  | 8,847,445 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 8,847,445 |
Mr Grant Chamberlain |  |  | 1,728,023 |  |  |  | 450,000 |  |  |  | — |  |  |  | (2,178,023 | )* |  |  | — |
Ms Lucy Turnbull |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,284,126 | ** |  |  | 3,284,126 |
Ms Deanne Miller |  |  | 2,963,892 |  |  |  | 600,000 |  |  |  | — |  |  |  | (796,587 | ) |  |  | 2,767,305 |
Dr Frédéric Triebel |  |  | 6,853,764 |  |  |  | 900,000 |  |  |  | — |  |  |  | — |  |  |  | 7,753,764 |
Total ordinary shares |  |  | 22,917,519 |  |  |  | 2,700,000 |  |  |  | — |  |  |  | 309,516 |  |  |  | 25,927,035 |
ADSs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mr Marc Voigt |  |  | 45 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 45 |
Dr Frédéric Triebel |  |  | — |  |  |  | 17,061 |  |  |  | — |  |  |  | — |  |  |  | 17,061 |
Total ADSs |  |  | 45 |  |  |  | 17,061 |  |  |  | — |  |  |  | — |  |  |  | 17,106 |
# | Other changes during the year includes on market acquisitions and/or disposals
* | This change during the year represents derecognition due to the cessation of the director’s position
** | This change during the year represents Ms Lucy Turnbull’s shareholding before she became director on February 25, 2022. The shareholding includes 2,981,626 shares held directly and 302,500 shares held indirectly.
|  |  |  |  | Received during the |  |  |  |  |  |  |  |  |  |
|  | Balance at start |  |  | fiscal year |  |  | Received during the |  |  | Other changes |  |  | Balance at end |
|  | of the |  |  | on exercise of |  |  | fiscal year on the |  |  | during the |  |  | of the |
June 30, 2021 |  | fiscal year |  |  | performance rights |  |  | exercise of options |  |  | fiscal year * |  |  | fiscal year |
Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr Russell Howard |  |  | 500,000 |  |  |  | 250,000 |  |  |  | — |  |  |  | — |  |  |  | 750,000 |
Mr Pete Meyers |  |  | 1,500,758 |  |  |  | 273,637 |  |  |  | — |  |  |  | — |  |  |  | 1,774,395 |
Mr Marc Voigt |  |  | 7,647,445 |  |  |  | 1,200,000 |  |  |  | — |  |  |  | — |  |  |  | 8,847,445 |
Mr Grant Chamberlain |  |  | 1,301,369 |  |  |  | 426,654 |  |  |  | — |  |  |  | — |  |  |  | 1,728,023 |
Ms Deanne Miller |  |  | 3,003,892 |  |  |  | 600,000 |  |  |  | — |  |  |  | (640,000 | ) |  |  | 2,963,892 |
Dr Frédéric Triebel |  |  | 5,953,764 |  |  |  | 900,000 |  |  |  | — |  |  |  | — |  |  |  | 6,853,764 |
Total ordinary shares |  |  | 19,907,228 |  |  |  | 3,650,291 |  |  |  | — |  |  |  | (640,000 | ) |  |  | 22,917,519 |
ADSs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mr Marc Voigt |  |  | 45 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 |
Total ADSs |  |  | 45 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 |
* | Other changes during the year include the shares acquired via the Entitlements Offer, on market acquisition and disposals.
Performance rights [member] |
Statement [LineItems] |
Summaries of All STI and LTI Performance Rights Granted Under the EIP | The number of performance rights over ordinary shares in the parent entity held during the year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below. On November 5, 2019, there was a 10 to 1 share consolidation. The number of performance rights in the fiscal years 2023, 2022 and 2021 tables below are prepared on post share consolidation basis.
|  |  |  |  |  |  |  |  |  |  |  |  |  | Balance at |  |  |  |  |  |  |
|  | Balance at |  |  |  |  |  |  |  |  |  |  |  | end |  |  |  |  |  |  |
|  | start of |  |  |  |  |  |  |  |  | Other |  |  | of the |  |  | Vested and |  |  |  |
June 30, 2023 |  | the fiscal year |  |  | Granted |  |  | Exercised |  |  | Changes |  |  | fiscal year |  |  | exercisable |  |  | Unvested |
Performance Rights over ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr. Russell Howard |  |  | 339,621 |  |  |  | — |  |  |  | (113,207 | ) |  |  | — |  |  |  | 226,414 |  |  |  | — |  |  |  | 226,414 |
Mr. Pete Meyers |  |  | 1,000,000 |  |  |  | 1,166,667 |  |  |  | (500,000 | ) |  |  | — |  |  |  | 1,666,667 |  |  |  | — |  |  |  | 1,666,667 |
Mr Marc Voigt |  |  | 6,000,000 |  |  |  | — |  |  |  | (2,400,000 | ) |  |  | — |  |  |  | 3,600,000 |  |  |  | — |  |  |  | 3,600,000 |
Dr. Frédéric Triebel |  |  | 3,600,000 |  |  |  | — |  |  |  | (900,000 | ) |  |  | — |  |  |  | 2,700,000 |  |  |  | — |  |  |  | 2,700,000 |
Ms Lucy Turnbull |  |  | — |  |  |  | 457,832 |  |  |  | (92,966 | ) |  |  | (364,866 | )* |  |  | — |  |  |  | — |  |  |  | — |
Ms Lis Boyce |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Ms Deanne Miller |  |  | 2,400,000 |  |  |  | — |  |  |  | (600,000 | ) |  |  | — |  |  |  | 1,800,000 |  |  |  | — |  |  |  | 1,800,000 |
|  |  | 13,339,621 |  |  |  | 1,624,499 |  |  |  | (4,606,173 | ) |  |  | (364,866 | ) |  |  | 9,993,081 |  |  |  | — |  |  |  | 9,993,081 |
* | The change during the year represents derecognition due to the cessation of the director’s position.
|  |  |  |  |  |  |  |  |  |  |  |  |  | Balance at |  |  |  |  |  |  |
|  | Balance at |  |  |  |  |  |  |  |  |  |  |  | end |  |  |  |  |  |  |
|  | start of |  |  |  |  |  |  |  |  | Other |  |  | of the |  |  | Vested and |  |  |  |
June 30, 2022 |  | the fiscal year |  |  | Granted |  |  | Exercised |  |  | Changes |  |  | fiscal year |  |  | exercisable |  |  | Unvested |
Performance Rights over ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr. Russell Howard |  |  | 250,000 |  |  |  | 339,621 |  |  |  | (250,000 | ) |  |  | — |  |  |  | 339,621 |  |  |  | — |  |  |  | 339,621 |
Mr. Pete Meyers |  |  | 1,500,000 |  |  |  | — |  |  |  | (500,000 | ) |  |  | — |  |  |  | 1,000,000 |  |  |  | — |  |  |  | 1,000,000 |
Mr. Marc Voigt |  |  | 2,400,000 |  |  |  | 3,600,000 |  |  |  | — |  |  |  | — |  |  |  | 6,000,000 |  |  |  | 1,200,000 |  |  |  | 4,800,000 |
Mr Grant Chamberlain |  |  | 1,350,000 |  |  |  | — |  |  |  | (450,000 | ) |  |  | (900,000 | )* |  |  | — |  |  |  | — |  |  |  | — |
Ms. Deanne Miller |  |  | 1,200,000 |  |  |  | 1,800,000 |  |  |  | (600,000 | ) |  |  | — |  |  |  | 2,400,000 |  |  |  | — |  |  |  | 2,400,000 |
Dr. Frédéric Triebel |  |  | 1,800,000 |  |  |  | 2,700,000 |  |  |  | (900,000 | ) |  |  | — |  |  |  | 3,600,000 |  |  |  | — |  |  |  | 3,600,000 |
|  |  | 8,500,000 |  |  |  | 8,439,621 |  |  |  | (2,700,000 | ) |  |  | (900,000 | ) |  |  | 13,339,621 |  |  |  | 1,200,000 |  |  |  | 12,139,621 |
* | The change during the year represents derecognition due to the cessation of the director’s position.
June 30, 2021 |  | Balance at start of the fiscal year |  |  | Granted |  |  | Exercised |  |  | Other Changes |  |  | Balance at end of the fiscal year |  |  | Vested and exercisable |  |  | Unvested |
Rights over ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr. Russell Howard |  |  | 500,000 |  |  |  | — |  |  |  | (250,000 | ) |  |  | — |  |  |  | 250,000 |  |  |  | — |  |  |  | 250,000 |
Mr. Pete Meyers |  |  | 1,773,637 |  |  |  | — |  |  |  | (273,637 | ) |  |  | — |  |  |  | 1,500,000 |  |  |  | — |  |  |  | 1,500,000 |
Mr. Marc Voigt |  |  | 3,600,000 |  |  |  | — |  |  |  | (1,200,000 | ) |  |  | — |  |  |  | 2,400,000 |  |  |  | — |  |  |  | 2,400,000 |
Mr Grant Chamberlain |  |  | 426,654 |  |  |  | 1,350,000 |  |  |  | (426,654 | ) |  |  | — |  |  |  | 1,350,000 |  |  |  | — |  |  |  | 1,350,000 |
Ms. Deanne Miller |  |  | 1,800,000 |  |  |  | — |  |  |  | (600,000 | ) |  |  | — |  |  |  | 1,200,000 |  |  |  | — |  |  |  | 1,200,000 |
Dr. Frédéric Triebel |  |  | 2,700,000 |  |  |  | — |  |  |  | (900,000 | ) |  |  | — |  |  |  | 1,800,000 |  |  |  | — |  |  |  | 1,800,000 |
|  |  | 10,800,291 |  |  |  | 1,350,000 |  |  |  | (3,650,291 | ) |  |  | — |  |  |  | 8,500,000 |  |  |  | — |  |  |  | 8,500,000 |

X
- Definition The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2023-01-01 -Paragraph 18 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | immp_StatementLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=immp_PerformanceRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |